tiprankstipranks
Blurbs

Barclays Keeps Their Buy Rating on Tango Therapeutics (TNGX)

In a report released today, Peter Lawson from Barclays maintained a Buy rating on Tango Therapeutics (TNGXResearch Report). The company’s shares opened today at $6.24.

Lawson covers the Healthcare sector, focusing on stocks such as Blueprint Medicines, Immunocore Holdings, and ImmunoGen. According to TipRanks, Lawson has an average return of 0.5% and a 41.37% success rate on recommended stocks.

Currently, the analyst consensus on Tango Therapeutics is a Strong Buy with an average price target of $16.33.

See the top stocks recommended by analysts >>

TNGX market cap is currently $544.1M and has a P/E ratio of -5.66.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BCTG Acquisition Corp is a blank check company.

Read More on TNGX:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles